Study guide

13.3 AKI Criteria, Tubular Injury, and CKD Staging

AHIMA Certified Documentation Integrity Practitioner CDIP

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Authoritative Coding Resources & Conventions

1.1 Official Coding Resources: Scope, Authority & Research 1.2 General Coding Conventions, Punctuation & Instructional Notes 1.3 Chapter-Specific and Setting-Specific Coding Guidelines

2 Chapter 2: Principal & Secondary Diagnosis Determination

2.1 UHDDS Definitions & Principal Diagnosis Selection 2.2 Two or More Diagnoses Equally Meeting Criteria 2.3 Secondary Diagnosis Reporting Standards & POA Status

3 Chapter 3: Procedure Coding & Sequencing Standards

3.1 ICD-10-PCS Root Operations & Inpatient Procedure Coding 3.2 Principal Procedure Selection & Surgical Sequencing 3.3 Applying Official References to Ambiguous Records

4 Chapter 4: Inpatient Prospective Payment & DRG Grouping

4.1 MS-DRG Logic, CC/MCC Exclusions & Severity Levels 4.2 Working vs. Final DRG Assignment & Optimization vs. Maximization 4.3 CDI-Coding Reconciliation & Annual Regulatory Updates

5 Chapter 5: Enterprise CDI Promotion & Program Value

5.1 Articulating CDI Value to C-Suite & Hospital Leadership 5.2 Organizational Models, Inpatient/Outpatient Scope & Staffing 5.3 Cross-Functional Collaboration: HIM, Quality & Case Management

6 Chapter 6: Cross-Functional Alignment & Improvement Projects

6.1 Partnering with Nursing, Pharmacy & Allied Health Professionals 6.2 Documentation Improvement Project Identification & Scoping 6.3 Executing, Piloting & Measuring CDI Project Outcomes

7 Chapter 7: Physician Champion Engagement & Clinical Advocacy

7.1 Selection, Role & Credibility of the CDI Physician Champion 7.2 Peer-to-Peer Engagement, Coaching & Overcoming Resistance 7.3 Developing Standard CDI Operational Policies & Procedures

8 Chapter 8: Compliant Policy Architecture & Query Governance

8.1 AHIMA/ACDIS Practice Brief Standards in Policy Construction 8.2 Medical Record Integration of Provider Query Responses 8.3 Policies for Electronic, Paper, and Verbal Query Communications

9 Chapter 9: Query Escalation & Professional Communication

9.1 Chain of Command & Protocols for Unanswered Queries 9.2 Conflict Resolution & Professional Feedback Mechanisms 9.3 Assessing Stakeholder Learning Needs & Specialty Curricula

10 Chapter 10: Educational Delivery & Broader Healthcare Impacts

10.1 Delivery Methods: Microlearning, Case Studies & Grand Rounds 10.2 Documentation Impacts on Clinical Research & Epidemiology 10.3 Documentation Impacts on Case Management, LOS & Reimbursement

11 Chapter 11: Clinical Record Synthesis & Encounter Trajectory

11.1 Synthesizing Provider Notes, Consults & Progress Trajectory 11.2 Interpreting Diagnostic Imaging, Pathology & Labs 11.3 Resolving Conflicting, Ambiguous & Copy-Forward Entries

12 Chapter 12: Advanced Clinical Concepts & Review Prioritization

12.1 Pharmacotherapy, Clinical Trajectories & Disease Correlations 12.2 Inpatient Review Prioritization: High-Risk & High-Volume 12.3 Payer Prioritization, Length of Stay & Re-Review Cadence

13 Chapter 13: Clinical Indicator Mapping & Gap Recognition

13.1 Systematic Identification of Documentation Gaps 13.2 Sepsis Definitions, SEP-1, and Coding 13.3 AKI Criteria, Tubular Injury, and CKD Staging

14 Chapter 14: Diagnostic Precision in High-Impact Conditions

14.1 Respiratory Failure: Acuity, Evidence, and Sequencing 14.2 Heart Failure Phenotype, Acuity, and Hypertensive Combinations 14.3 Encephalopathy, Delirium, and Acute Cognitive Change

15 Chapter 15: Clinical Validation & Complication Discrepancies

15.1 Malnutrition Assessment, Severity, and Provider Documentation 15.2 Principles of a Compliant, Nonleading Query 15.3 Open-Ended, Multiple-Choice, and Yes/No Queries

16 Chapter 16: Query Mechanics & Direct Provider Collaboration

16.1 Electronic Query Systems, Templates, and Technology Oversight 16.2 Collaborating With the Appropriate Query Recipient 16.3 Capturing and Clarifying Query Responses

17 Chapter 17: Quality Indicators & Post-Discharge Clarification

17.1 Present on Admission Clarification and Selected HAC Rules 17.2 Clarifying Acuity, Cause, Site and Severity 17.3 Post-Discharge Query Opportunities and Limits 17.4 Managing Post-Discharge Query Workflows

18 Chapter 18: CDI Operational Dashboards & Quality Auditing

18.1 Departmental Metrics: Definitions, Calculations and Dashboard Use 18.2 Internal CDI Quality Audits and Reviewer Calibration 18.3 Query Trends: Understanding the Process and Provider Experience

19 Chapter 19: Benchmarking, Productivity & Data-Driven Workflow

19.1 Provider Documentation Benchmarking 19.2 External Benchmarking: CMI, Severity, Mortality and Length of Stay 19.3 Evaluating CDI Professional Performance 19.4 Using Data to Design CDI Workflow and Staffing

20 Chapter 20: Ethical CDI Standards & Regulatory Frameworks

20.1 Applying AHIMA Ethics to CDI Decisions 20.2 Responding to Financial Pressure and Upcoding Risks 20.3 Maintaining Competence and Professional Integrity

21 Chapter 21: Regulatory Compliance & Enforcement Landscapes

21.1 False Claims, Overpayments and Referral Laws 21.2 Regulatory Agencies, Review Contractors and Appeals 21.3 EHR Templates, Copied Text and Record Integrity

22 Chapter 22: Technology Risks & Second-Level Review Protocols

22.1 CAC, NLP and AI: Context, Oversight and Performance 22.2 Selecting Cases for Second-Level Review 22.3 Conducting and Closing a Second-Level Review

23 Chapter 23: Clinical Validation Queries & Risk Mitigation

23.1 Clinical Validation and Coding Clarification 23.2 Clinical Validation Queries and Denial Evidence 23.3 Detecting Leading, Biased and Unsupported Queries

24 Chapter 24: Noncompliant Query Remediation & Query Lifecycle Management

24.1 Query Remediation and Corrective Action 24.2 Query Timeframes, Aging and Measurement 24.3 Query Records, Retention and Evidence Preservation

13.3 AKI Criteria, Tubular Injury, and CKD Staging

Key Takeaways Explain This Topic AI

The final 2012 AKI criteria use a timed creatinine increase or urine-output route; apply the highest qualifying stage. The 2026 AKI/AKD update remains a draft at this review date.

Rapid improvement does not automatically negate AKI, and neither a single urine index nor persistent creatinine elevation independently establishes ATN.

CKD requires abnormalities present for at least three months and is classified by cause, GFR category, and albuminuria. One abnormal eGFR does not establish chronicity or authorize coder-assigned staging.

Acute dialysis does not itself establish ESRD; transplant status does not automatically mean ongoing ESRD or a transplant complication.

Hypertensive CKD presumption requires an indication of nonrelationship to be removed. Apply all associated-condition/stage instructions and distinguish clinical AKI stage from CC/MCC classification.

Last updated: October 2026

Acute kidney injury, tubular injury, and chronic kidney disease

Renal review asks three different questions: Has kidney function changed acutely? What mechanism does the clinician identify? What chronic disease was already present? These questions affect care, documentation, and coding in different ways. A creatinine-based AKI stage does not identify its cause, and neither a laboratory value nor a dialysis order independently supplies every diagnosis in the code set.

Source status matters. At this guide's October 23, 2026 review, KDIGO's AKI page identifies its 2026 AKI/AKD update as a public-review draft being prepared for publication and still links the final 2012 guideline. The criteria below are explicitly the final KDIGO 2012 criteria , not adoption of a draft as a final standard. The CKD discussion uses the final 2024 guideline; the separate medication-focused update under public review is not substituted for it.

Recognize the AKI criteria and time windows

KDIGO 2012 defines AKI by any of these findings:

Serum creatinine increases by at least 0.3 mg/dL within 48 hours .

Serum creatinine reaches at least 1.5 times baseline , with the increase known or presumed to have occurred within the preceding seven days.

Urine volume is below 0.5 mL/kg/hour for six hours .

Creatinine and urine output provide alternative routes; both are not required. Check measurement times, units, baseline reliability, body weight used for urine-output calculations, and whether urine collection is complete. A copied “low urine output” statement without a measured interval is not interchangeable with six hours of documented output.

Staging after AKI is identified

  • KDIGO 2012 stage Creatinine or other qualifying route Urine-output route
  • 1 1.5–1.9 times baseline, or an increase of at least 0.3 mg/dL Below 0.5 mL/kg/hour for 6–12 hours
  • 2 2.0–2.9 times baseline Below 0.5 mL/kg/hour for at least 12 hours

3 At least 3 times baseline, increase to at least 4.0 mg/dL, or initiation of renal replacement therapy; the guideline also has a pediatric eGFR route Below 0.3 mL/kg/hour for at least 24 hours, or anuria for at least 12 hours

Use the highest qualifying stage when routes differ. At twelve hours of urine output below 0.5 mL/kg/hour, the stage 2 threshold is met. The stage 3 absolute-creatinine route requires the acute change specified in the AKI definition; stable chronic creatinine of 4.2 mg/dL does not automatically become stage 3 AKI. Similarly, existing maintenance dialysis is not “new initiation of renal replacement therapy” for an acute event.

For patients younger than 18, the 2012 table includes a decrease in eGFR below 35 mL/min/1.73 m² as a stage 3 route. Apply age-appropriate clinical interpretation and the guideline's qualifications. These criteria assist the clinician; CDI must not independently assign a diagnosis merely because an EHR calculator flags a stage.

Work the numbers and preserve the timeline

A verified creatinine of 1.0 mg/dL on Monday rises to 2.4 mg/dL on Tuesday. The increase is 1.4 mg/dL and the ratio is 2.4. The creatinine route supports stage 2 under the specified framework. If urine output is 0.4 mL/kg/hour throughout twelve hours, that independently reaches stage 2. Stage 3 does not follow merely because the creatinine exceeds 2.0 mg/dL.

When the only available comparison is an old value, the required acute timing needs clinical assessment rather than an invented normal baseline. The 2026 query brief permits relevant prior records in a current clinical scenario. Use them with their actual dates and limitations; an old normal value is not proof that all change occurred during the last seven days. Uncertainty can support asking whether the process is acute, chronic, or acute on chronic.

Separate syndrome from mechanism

AKI can involve reduced kidney perfusion, intrinsic kidney disease or injury, obstruction, or several mechanisms together. A response to volume restoration can inform the clinician's assessment but does not automatically negate AKI. The KDIGO discussion specifically cautions against calling an acute reduction in kidney function benign merely because tubular concentration is preserved.

Acute tubular necrosis (ATN) is a clinical syndrome associated with tubular injury, often considered in ischemic or toxic contexts. Its name does not mean that every clinical case requires biopsy-proven widespread cell death. The 2012 guideline explains the mismatch between the term and the limited morphologic changes sometimes found in human disease. A fixed requirement for 7–21 days of oliguria or a mandatory three-phase course is inappropriate.

Urine sediment, exposure history, perfusion, serial kidney function, and response to treatment may inform the differential. Muddy brown granular casts can strongly support tubular injury. Fractional sodium excretion is contextual evidence, not a binary ATN classifier. In a prospective inpatient study, low fractional sodium excretion occurred in many patients with muddy brown casts; a value below 1% therefore did not exclude tubular injury. Do not use a single sodium-excretion, urea-excretion, BUN/creatinine, or osmolality cutoff as a universal rule-in/rule-out test.

If the record describes persistent AKI after shock but only lists “azotemia,” ask the involved provider to clarify the renal condition and, where supported, its mechanism. Present the actual findings and credible alternatives. Do not ask for ATN because it carries an MCC, or imply that a slower creatinine recovery proves necrosis. When terminology such as tubular injury leaves the intended coded condition unclear, resolve that specific ambiguity rather than silently substituting a preferred diagnosis.

CKD is more than a single eGFR

KDIGO 2024 defines CKD by kidney structure or function abnormalities with health implications present for at least three months . It classifies CKD by cause, GFR category, and albuminuria category (CGA) . The GFR categories are:

  • Clinical GFR category GFR, mL/min/1.73 m² Corresponding ICD-10-CM stage code when documented
  • G1 At least 90 N18.1
  • G2 60–89 N18.2
  • G3a 45–59 N18.31
  • G3b 30–44 N18.32
  • G4 15–29 N18.4
  • G5 Below 15 N18.5, unless ESRD documentation/instructions apply

G1 or G2 alone does not establish CKD without evidence of kidney damage. Chronicity can be supported by prior results, imaging, pathology, history, or repeat assessment; one abnormal eGFR or albumin/creatinine ratio does not establish it. A low eGFR during an acute illness may reflect an acute process. CDI evaluates the history and provider assessment rather than deriving a chronic stage from that isolated result.

CKD stage is a provider diagnosis, outside the routine nonprovider documentation exceptions in I.B.14. If stage 3 is documented without a supported subdivision, N18.30 is available. Query when there is a meaningful, supported unresolved question; do not force a 3a/3b answer solely because a laboratory system prints an estimate.

ESRD, dialysis, and transplant status

FY 2027 I.C.14.a directs N18.6 when the provider documents ESRD. If a CKD stage and ESRD are both documented, assign N18.6 only. The Tabular List also includes CKD requiring chronic dialysis under N18.6 and directs an additional dialysis-status code. An acute dialysis episode for AKI does not, by itself, establish chronic dialysis dependence or ESRD.

A transplant recipient can still have CKD. Documented CKD after a transplant is not automatically a transplant complication and does not mean every recipient should retain ESRD coding. Apply the documented CKD stage and kidney-transplant status, with separate complication guidance when failure, rejection, or another transplant complication is established. Query a genuinely unclear complication relationship.

Apply the coding relationships and severity rules

When AKI and CKD are established, both N17.- and the appropriate N18.- code may be needed. Principal diagnosis depends on the circumstances of admission and applicable conventions; an acute abnormal result does not automatically make AKI principal.

Hypertension and CKD are presumed related under I.C.9.a.2 unless the provider indicates that the CKD is not related to hypertension . Another documented CKD cause alone does not establish that exception. Use I12 with the stage code when applicable; qualifying heart involvement with hypertension and CKD can require I13 and additional heart-failure/stage codes. Follow N18's code-first instructions for associated diabetic or hypertensive CKD rather than treating the CKD stage as the entire code set.

The FY 2027 Index maps azotemia to R79.89, with a different route when it means uremia. Do not automatically replace it with R39.89 or dehydration. N17.9 includes nontraumatic AKI, while N17.0 describes acute kidney failure with tubular necrosis. In final MS-DRG v44, N17.9 is a CC and N17.0 an MCC; N18.4 and N18.5 are CCs, while N18.6 is an MCC. These secondary-diagnosis classifications remain subject to exclusions and complete grouping. A clinical AKI stage is not itself a CC/MCC category, and a renal code does not guarantee an individual risk-model or payment result.

Sources: KDIGO AKI guideline status ; final KDIGO 2012 AKI guideline, 1.1 and 2.1 ; KDIGO CKD guideline status ; final KDIGO 2024 CKD guideline, tables 1–3 and 1.1.3 ; prospective urine-sediment/FENa study ; FY 2027 ICD-10-CM guidelines ; FY 2027 Index and Tabular List ; final MS-DRG v44 Appendix C ; 2026 query brief, X .